Gene Editing Stocks Pull Back On New CRISPR Study

CRSP and NTLA could be finding chart support, though

Jul 16, 2018 at 2:28 PM
facebook X logo linkedin


U.S. stocks are sluggish today, as lower oil prices weigh on the major indexes. One group in particular that's under pressure is gene editing stocks, following another concerning study on CRISP/Cas9. As such, CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics Inc (NASDAQ:NTLA), and Editas Medicine Inc (NASDAQ:EDIT) are all lower. Below, we'll take a closer look at the fallout surrounding shares of CRSP, NTLA, and EDIT.

CRSP Falls Back Below 50-Day Moving Average

CRSP stock is trading down 7.5% at $60.80, and while it's fallen back below the 50-day moving average and onto the short sale restricted list, it remains atop a line of higher lows that's been in place all year. In fact, the 200-day moving average for CRISPR Therapeutics still sits all the way down near $40. Many traders have continued to bet against the company, however, potentially hoping for more negative headlines in the futures. Short interest rose another 10.8% in the last two reporting periods, and now represents 18% of the security's total float. In a similar vein, the July 50, 55, and 60 put options are all home to heavy open interest.

Calls See Action Amid NTLA Slide

NTLA shares are down 7.2% at $30.25, but are also holding their recent channel of higher highs and lows. They also earlier found strong support from the 20-day moving average. Some options traders are expecting the stock to hold above the $30 level, too, with buy-to-open action seemingly taking place today at the January 2019 30-strike call.

Sentiment in the analyst community is also very upbeat toward Intellia, with all but one covering brokerage firm handing out anything lower than a "strong buy" rating. Moreover, the average 12-month price target stands up at $48.75.

July Puts Popular on EDIT

Finally, EDIT stock has shed 5.3% to trade at $35.89, but remains above the 100% year-over-year level. Unlike NTLA, puts are popular, trading at more than double the expected pace, led by action at the July 35 put. Elsewhere, recent short sellers should be happy about the shares' decline, since short interest on Editas rose by 11.4% in the last reporting period to 5.7 million shares -- or 5.5 times the equity's average daily trading volume.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI